Contrasting Cartesian Therapeutics (RNAC) & Its Rivals

Cartesian Therapeutics (NASDAQ:RNAC) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Cartesian Therapeutics to related companies based on the strength of its earnings, dividends, valuation, analyst recommendations, risk, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cartesian Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	8	0	2.80
Cartesian Therapeutics Competitors	7768	21187	48893	1232	2.55

Cartesian Therapeutics presently has a consensus price target of $42.86, suggesting a potential upside of 125.33%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.92%. Given Cartesian Therapeutics’ rivals higher probable upside, analysts clearly believe Cartesian Therapeutics has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Cartesian Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cartesian Therapeutics	$47.94 million	-$219.71 million	-0.36
Cartesian Therapeutics Competitors	$9.58 billion	$147.39 million	-5.43

Cartesian Therapeutics’ rivals have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cartesian Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Cartesian Therapeutics Competitors	-3,590.11%	-276.96%	-39.10%

Risk and Volatility

Cartesian Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ rivals have a beta of 3.71, meaning that their average share price is 271% more volatile than the S&P 500.

Summary

Cartesian Therapeutics beats its rivals on 8 of the 13 factors compared.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.